<DOC>
	<DOCNO>NCT02938858</DOCNO>
	<brief_summary>The registry aim compare two first-line available treatment approach non-high-risk APL patient age ≤ 70 year - ATRA plus chemotherapy ATRA plus ATO - term practitioner 's choice two option , clinical effectiveness cost-effectiveness , long-term outcome , short- long-term toxic effect .</brief_summary>
	<brief_title>French Registry First-line Treatment Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>- Collection epidemiological data non-high-risk APL patient age ≤ 70 year : age sex distribution , medical history , prognostic factor ( time treatment start , severity coagulopathy presentation , Performance status… ) . - Documentation clinical biologic effectiveness two first-line treatment approach available non-high-risk APL patient . - Documentation Minimal Residual Disease ( MRD ) . - Correlation clinical outcome choose therapy . - Validation publish prognostic factor identification new prognostic factor</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<criteria>Newlydiagnosed APL ( either de novo therapyrelated ) base cytologic criterion confirm presence ( 15 ; 17 ) translocation and/or detection fusion transcript PML/RARα . Nonhighrisk APL ( White Blood Count &lt; 10000/μl presentation ) Age ≤ 70 year Relapsed APL Newlydiagnosed Highrisk APL ( White Blood Count &gt; 10000/μl presentation ) Age &gt; 70 year</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>